Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance

MT Newswires Live

Jan 15, 2025

Myriad Genetics (MYGN) said Wednesday it expects Q4 adjusted earnings of $0.03 to $0.04 per diluted share.

Analysts surveyed by FactSet expect $0.03.

Revenue for the quarter ended Dec. 31 is expected to be in the range of $209 million to $211 million, up by about 6% to 7% from a year earlier.

Analysts polled by FactSet expect $212.9 million.

The company said it now expects 2024 adjusted EPS of $0.14 to $0.15, versus its prior guidance for $0.12 to $0.14, while revenue is now expected to be between $836 million and $838 million, compared with its guidance for $837 million to $843 million. Analysts polled by FactSet expect adjusted EPS of $0.13 on revenue of $840 million.

For 2025, the company said it expects adjusted EPS of $0.07 to $0.11 on revenue of $840 million to $860 million. Analysts surveyed by FactSet expect adjusted EPS of $0.15 on revenue of $879.5 million.

Myriad Genetics said it intends to release its actual Q4 and full-year 2024 results in February.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503406476"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503406476\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503406476?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503406476","market":"sh","top_or_hot":-1,"title":"Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance","media":"MT Newswires Live","content":"<html><body><p> Myriad Genetics (MYGN) said Wednesday it expects Q4 adjusted earnings of $0.03 to $0.04 per diluted share.</p><p>Analysts surveyed by FactSet expect $0.03.</p><p>Revenue for the quarter ended Dec. 31 is expected to be in the range of $209 million to $211 million, up by about 6% to 7% from a year earlier.</p><p>Analysts polled by FactSet expect $212.9 million.</p><p>The company said it now expects 2024 adjusted EPS of $0.14 to $0.15, versus its prior guidance for $0.12 to $0.14, while revenue is now expected to be between $836 million and $838 million, compared with its guidance for $837 million to $843 million. Analysts polled by FactSet expect adjusted EPS of $0.13 on revenue of $840 million.</p><p>For 2025, the company said it expects adjusted EPS of $0.07 to $0.11 on revenue of $840 million to $860 million. Analysts surveyed by FactSet expect adjusted EPS of $0.15 on revenue of $879.5 million.</p><p>Myriad Genetics said it intends to release its actual Q4 and full-year 2024 results in February.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-15 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Myriad Genetics (MYGN) said Wednesday it expects Q4 adjusted earnings of $0.03 to $0.04 per diluted share.</p><p>Analysts surveyed by FactSet expect $0.03.</p><p>Revenue for the quarter ended Dec. 31 is expected to be in the range of $209 million to $211 million, up by about 6% to 7% from a year earlier.</p><p>Analysts polled by FactSet expect $212.9 million.</p><p>The company said it now expects 2024 adjusted EPS of $0.14 to $0.15, versus its prior guidance for $0.12 to $0.14, while revenue is now expected to be between $836 million and $838 million, compared with its guidance for $837 million to $843 million. Analysts polled by FactSet expect adjusted EPS of $0.13 on revenue of $840 million.</p><p>For 2025, the company said it expects adjusted EPS of $0.07 to $0.11 on revenue of $840 million to $860 million. Analysts surveyed by FactSet expect adjusted EPS of $0.15 on revenue of $879.5 million.</p><p>Myriad Genetics said it intends to release its actual Q4 and full-year 2024 results in February.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2503406476","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503406476","pubTimestamp":1736952793,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Myriad Genetics  said Wednesday it expects Q4 adjusted earnings of $0.03 to $0.04 per diluted share.Analysts surveyed by FactSet expect $0.03.Revenue for the quarter ended Dec. 31 is expected to be in the range of $209 million to $211 million, up by about 6% to 7% from a year earlier.Analysts polled by FactSet expect $212.9 million.The company said it now expects 2024 adjusted EPS of $0.14 to $0.15, versus its prior guidance for $0.12 to $0.14, while revenue is now expected to be between $836 million and $838 million, compared with its guidance for $837 million to $843 million. Analysts polled by FactSet expect adjusted EPS of $0.13 on revenue of $840 million.For 2025, the company said it expects adjusted EPS of $0.07 to $0.11 on revenue of $840 million to $860 million. Analysts surveyed by FactSet expect adjusted EPS of $0.15 on revenue of $879.5 million.Myriad Genetics said it intends to release its actual Q4 and full-year 2024 results in February.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"Myriad Genetics预计第四季度收入将更高，并提供2025年指导","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (MYGN) said Wednesday it expects Q4 adjusted earnings of $0.03 to $0.04 per diluted share.Analysts surveyed by FactSet expect $0.03.Revenue for the quarter ended Dec. 31 is expected to be in the range of $209 million to $211 million, up by about 6% to 7% from a year earlier.Analysts polled by FactSet expect $212.9 million.The company said it now expects 2024 adjusted EPS of $0.14 to $0.15, versus its prior guidance for $0.12 to $0.14, while revenue is now expected to be between $836 million and $838 million, compared with its guidance for $837 million to $843 million. Analysts polled by FactSet expect adjusted EPS of $0.13 on revenue of $840 million.For 2025, the company said it expects adjusted EPS of $0.07 to $0.11 on revenue of $840 million to $860 million. Analysts surveyed by FactSet expect adjusted EPS of $0.15 on revenue of $879.5 million.Myriad Genetics said it intends to release its actual Q4 and full-year 2024 results in February.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}